Nu Skin earnings missed by $0.04, revenue topped estimates

Nu Skin (NYSE: NUS) reported Q2 EPS of $0.21, missing analyst estimates, but revenue of $386.1M exceeded consensus. Crucially, the company issued significantly stronger full-year 2025 EPS guidance of $3.05-$3.25, far surpassing the $0.99 analyst consensus, alongside favorable Q3 2025 revenue and EPS outlooks. This robust forward guidance, particularly for FY25 profitability, appears to be the primary takeaway, potentially overshadowing the Q2 EPS shortfall and indicating a more optimistic trajectory than previously anticipated.

Analysis

Nu Skin (NUS) presented a mixed second-quarter report, characterized by a revenue beat but a miss on profitability. The company posted revenue of $386.1 million, surpassing the consensus estimate of $376.67 million, but delivered earnings per share of $0.21, which was $0.04 below analyst expectations. The central, and most impactful, element of the release is the company's forward guidance. Management issued an exceptionally strong full-year 2025 EPS forecast of $3.05-$3.25, representing a more than threefold increase over the current analyst consensus of $0.99. This suggests a significant operational turnaround or profitability inflection is anticipated. Near-term guidance for Q3 2025 is broadly in-line with expectations, with EPS projected at $0.25-$0.35 (vs. $0.29 consensus) and revenue at $360-$390 million (vs. $366.10M consensus), providing a stable bridge to the guided long-term growth. Despite the stock's 21.35% decline over the last 12 months, this aggressive FY25 outlook appears to be overriding the recent EPS miss, reflected in the strongly positive sentiment signals.

Key Decisions for Investors

• Investors should prioritize the company's highly optimistic full-year 2025 EPS guidance of $3.05-$3.25, as this forecast, which dramatically exceeds the $0.99 consensus, is the primary bullish catalyst overshadowing the Q2 earnings miss.
• Monitor subsequent quarterly reports for tangible evidence of margin expansion and operational execution that validates the path toward the ambitious 2025 profitability targets, as this guidance now sets a high bar for future performance.
• Given the stock's recent 19.59% gain and the 'fair performance' financial health rating, consider the risk-reward profile, weighing the potential for a significant turnaround against the execution risk required to achieve such a substantial earnings ramp-up.